Acute renal allograft rejection in patients with Epstein-Barr virus associated post-transplant lymphoproliferative disorder

Clinical Transplantation

Volumn 11, Issue 6, 1997, Pages 574-576

  Purighalla, Raman ^a   Shapiro, Ron ^a   Jordan, Mark L ^a   Scantlebury, Velma P ^a   Gritsch, H Albin ^a   Vivas, Carlos ^a   Randhawa, Parmjeet S ^a,b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b PRESBYTERIAN UNIVERSITY HOSPITAL   (United States)

Author keywords

Epstein Barr virus; Post transplant lymphoproliferative disorder; Rejection, renal

Indexed keywords

OKT 3;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DISEASE COURSE; EPSTEIN BARR VIRUS; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT REJECTION; LYMPHOPROLIFERATIVE DISEASE; MALE; PRIORITY JOURNAL; RECIPIENT;

ADULT; AGED; FEMALE; GLUCOCORTICOIDS; GRAFT REJECTION; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; MUROMONAB-CD3;

EID: 0030715067     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. SHAPIRO RS, MCCLAIN K, FRIZZERA G, et al. Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood 1988: 71: 1234.
2. COHEN JI. Epstein-Barr virus lymphoproliferative disease associated with acquired immunodeficiency. Medicine 1991: 70: 137.
3. PENN I. Immunosuppression. A contributory factor in lymphoma formation. Clin Transpl 1992 (Special issue): 6: 214.
4. CHU SH, LAI MK, HUANG CC, CHUANG CK. Lymphoma in cyclosporine treated renal transplant recipients. Transpl Proc 1992: 24: 1594.
5. STARZL TE, NALESNIK MA, PORTER KA, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporine-steroid therapy. The Lancet 1984: 1: 583.
6. HANTO DW, SAKAMOTO K, PURTILO DT, SIMMONS RL, NAJARIAN JS. The Epstein-Barr virus in the pathogenesis of posttransplant lymphoproliferative disorders. Surgery 1981: 90: 204.
7. NALESNIK MA, JAFFE R, STARZL TE, et al. The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol 1988: 133: 173.
8. DEAMANT FD, ALBUJAR PF, CHEN YY, WEISS LM. Epstein-Barr virus distribution in neoplastic lymph nodes. Mod Pathol 1993: 6: 729.
9. SHAPIRO R, JORDAN M, SCANTLEBURY VP, et al. Renal transplantation at the University of Pittsburgh: The impact of FK506. In: Terasaki PI, Cecka MJ, eds. Clinical Transplants. Los Angeles: UCLA Tissue Typing Laboratory, 1994, 229.
10. SWINNEN LJ, MULLEN GM, CARR TJ, COSTANZO MR, FISHER RI. Aggressive treatment for postcardiac transplant lymphoproliferation. Blood 1995: 86: 3333.
11. MALATACK JJ, GARTNER JC, URBACH AH, ZITELLI BJ. Orthotopic liver transplantation, Epstein-Barr virus, cyclosporine, and lymhoproliferative disease: A growing concern. J Pediatr 1991: 118: 667.
12. KENAGY DN, SCHLESINGER Y, WECK K, RITTER JH, GAUDREAULT-KEENER MM, STORCH GA. Epstein-Barr virus DNA in peripheral blood leukocytes of patients with posttransplant lymphoproliferative disease. Transplantation 1995: 60: 547.